WO2004084939A8 - Hiv-peptide-carrier-conjugates - Google Patents

Hiv-peptide-carrier-conjugates

Info

Publication number
WO2004084939A8
WO2004084939A8 PCT/EP2004/003163 EP2004003163W WO2004084939A8 WO 2004084939 A8 WO2004084939 A8 WO 2004084939A8 EP 2004003163 W EP2004003163 W EP 2004003163W WO 2004084939 A8 WO2004084939 A8 WO 2004084939A8
Authority
WO
WIPO (PCT)
Prior art keywords
cpg
vlps
hiv peptides
vlp
immune response
Prior art date
Application number
PCT/EP2004/003163
Other languages
French (fr)
Other versions
WO2004084939A2 (en
WO2004084939A3 (en
Inventor
Martin F Bachmann
Adrian Huber
Vania Manolova
Edwin Meijerink
Karl G Proba
Alain Tissot
Original Assignee
Cytos Biotechnology Ag
Martin F Bachmann
Adrian Huber
Vania Manolova
Edwin Meijerink
Karl G Proba
Alain Tissot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag, Martin F Bachmann, Adrian Huber, Vania Manolova, Edwin Meijerink, Karl G Proba, Alain Tissot filed Critical Cytos Biotechnology Ag
Priority to CA002519165A priority Critical patent/CA2519165A1/en
Priority to EP04723204A priority patent/EP1605972A2/en
Priority to AU2004224761A priority patent/AU2004224761A1/en
Priority to US10/550,580 priority patent/US20060210588A1/en
Publication of WO2004084939A2 publication Critical patent/WO2004084939A2/en
Publication of WO2004084939A3 publication Critical patent/WO2004084939A3/en
Publication of WO2004084939A8 publication Critical patent/WO2004084939A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular HIV peptides linked thereto. Such CpG-VLPs are dramatically more immunogenic that their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against HIV peptides optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against HIV peptides are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
PCT/EP2004/003163 2003-03-26 2004-03-25 Hiv-peptide-carrier-conjugates WO2004084939A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002519165A CA2519165A1 (en) 2003-03-26 2004-03-25 Hiv-peptide-carrier-conjugates
EP04723204A EP1605972A2 (en) 2003-03-26 2004-03-25 Hiv-peptide-carrier-conjugates
AU2004224761A AU2004224761A1 (en) 2003-03-26 2004-03-25 HIV-peptide-carrier-conjugates
US10/550,580 US20060210588A1 (en) 2003-03-26 2004-03-25 Hiv-peptide-carrier-conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45734803P 2003-03-26 2003-03-26
US60/457,348 2003-03-26

Publications (3)

Publication Number Publication Date
WO2004084939A2 WO2004084939A2 (en) 2004-10-07
WO2004084939A3 WO2004084939A3 (en) 2005-03-31
WO2004084939A8 true WO2004084939A8 (en) 2005-06-09

Family

ID=33098221

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP2004/003163 WO2004084939A2 (en) 2003-03-26 2004-03-25 Hiv-peptide-carrier-conjugates
PCT/EP2004/003165 WO2004084940A1 (en) 2003-03-26 2004-03-25 Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
PCT/EP2004/003164 WO2004085635A1 (en) 2003-03-26 2004-03-25 Melan-a peptide analogue-virus-like-particle conjugates

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/EP2004/003165 WO2004084940A1 (en) 2003-03-26 2004-03-25 Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
PCT/EP2004/003164 WO2004085635A1 (en) 2003-03-26 2004-03-25 Melan-a peptide analogue-virus-like-particle conjugates

Country Status (13)

Country Link
US (2) US7517520B2 (en)
EP (3) EP1606398A1 (en)
JP (1) JP5022028B2 (en)
KR (1) KR20050115913A (en)
CN (2) CN100560719C (en)
AU (3) AU2004224762B2 (en)
BR (1) BRPI0408623A (en)
CA (3) CA2517675A1 (en)
MX (1) MXPA05009289A (en)
NZ (1) NZ542323A (en)
RU (1) RU2351362C2 (en)
WO (3) WO2004084939A2 (en)
ZA (3) ZA200507063B (en)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
ES2335979T3 (en) * 2001-09-14 2010-04-07 Cytos Biotechnology Ag IMMUNOSTIMULATOR CPG PACKAGING IN VIRUS SIMILAR PARTICLES: PREPARATION METHOD AND ITS USE.
EP1513552B1 (en) * 2002-06-20 2010-12-01 Cytos Biotechnology AG Packaged virus-like particles in combination with cpg for use as adjuvants with allergens : method of preparation and use
US7138252B2 (en) * 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
DE60336902D1 (en) * 2002-07-19 2011-06-09 Cytos Biotechnology Ag VACCINE COMPOSITIONS CONTAINING AMYLOID BETA 1-6 ANTIGENARRAYS
EP2241325B1 (en) 2002-10-29 2012-02-08 Coley Pharmaceutical Group, Inc. Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
AU2004224762B2 (en) * 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US8153426B2 (en) 2004-08-19 2012-04-10 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma-delta T cells and use in immunotherapy
WO2006037787A2 (en) * 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
KR100721928B1 (en) * 2004-11-05 2007-05-28 주식회사 바이오씨에스 Pharmaceutical composition for treating or preventing dermatitis comprising CpG oligodeoxynucleotide
ATE521621T1 (en) * 2004-11-29 2011-09-15 Changchun Huapu Biotechnology Co Ltd CPG SINGLE STRAND DESOXYNUCLEOTIDES FOR USE AS ADJUVANTS
US20090068224A1 (en) * 2005-01-31 2009-03-12 Vaxinnate Corporation Method to identify polypeptide toll-like receptor (tlr) ligands
BRPI0608455A2 (en) * 2005-03-18 2010-01-05 Cytos Biotechnology Ag a composition comprising cat allergen conjugates as well as vaccines, pharmaceutical compositions and medicaments containing them, and a process for their production
US20110008831A1 (en) * 2005-05-26 2011-01-13 Cytos Biotechnology Ag Scalable fermentation process
KR20080015854A (en) * 2005-06-14 2008-02-20 사이토스 바이오테크놀로지 아게 Antigen conjugates and uses thereof
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
FR2887457B1 (en) 2005-06-23 2007-10-05 Fond Bettencourt Schueller TRANSCUTANE TARGETING VACCINATION
PT2179737E (en) * 2005-07-01 2013-12-05 Index Pharmaceuticals Ab Modulating responsiveness to steroids
PL2269622T3 (en) * 2005-07-01 2014-05-30 Index Pharmaceuticals Ab CpG oligonucleotides used for enhancing steroid activity in a steroid dependent patient
US7468186B2 (en) * 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
BRPI0504117A (en) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epitopes, combination of epitopes, uses of epitopes or their combination, composition, uses of composition, anti-HIV-1 prophylactic vaccines, therapeutic vaccines, method for identifying epitopes and methods for treatment or prevention.
WO2007039458A2 (en) * 2005-09-21 2007-04-12 Cytos Biotechnology Ag Hiv peptide conjugates and uses thereof
CA2625969A1 (en) * 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
US20080044438A1 (en) * 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
SG172696A1 (en) 2006-06-12 2011-07-28 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
AU2013204383B2 (en) * 2006-06-12 2016-09-22 Kuros Us Llc Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
WO2008024427A2 (en) * 2006-08-23 2008-02-28 Science & Technology Corporation @ Unm A virus-like platform for rapid vaccine discovery
US8586728B2 (en) 2006-12-12 2013-11-19 Cytos Biotechnology Ag Oligonucleotides containing high concentrations of guanine monomers
WO2008071774A1 (en) * 2006-12-14 2008-06-19 Cytos Biotechnology Ag Purification process for coat protein of rna bacteriophages
CN104001170B (en) 2008-06-27 2016-08-24 硕腾有限责任公司 Novel adjunvant composition
BRPI0923225A2 (en) 2008-12-02 2016-10-04 Chiralgen Ltd Phosphorus-modified nucleic acid synthesis method
EP2376108B1 (en) * 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
WO2010122164A1 (en) 2009-04-23 2010-10-28 Cytos Biotechnology Ag VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
EA022699B1 (en) 2009-05-27 2016-02-29 Селекта Байосайенсиз, Инк. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US8431530B2 (en) 2009-06-12 2013-04-30 Morehouse School Of Medicine Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
MX342945B (en) 2009-07-06 2016-10-18 Ontorii Inc * Novel nucleic acid prodrugs and methods use thereof.
DE102009034779A1 (en) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetic analogues of bacterial lipopeptides and their application for the therapy and prophylaxis of allergic diseases
KR20210149203A (en) * 2009-11-02 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
WO2011109422A2 (en) 2010-03-02 2011-09-09 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
JP6199036B2 (en) 2010-03-16 2017-09-20 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ Tumor vaccination involved in humoral immune response to self-protein
EP2366709A1 (en) * 2010-03-16 2011-09-21 BioNTech AG Tumor vaccination involving a humoral immune response against self-proteins
CN107029223A (en) 2010-05-26 2017-08-11 西莱克塔生物科技公司 Synthesize nano-carrier combined vaccine
EP2407534A1 (en) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions
US9511135B2 (en) 2010-09-14 2016-12-06 Stc.Unm Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods
JP5868324B2 (en) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ Asymmetric auxiliary group
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
GB201021867D0 (en) * 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
US20120301498A1 (en) 2011-04-29 2012-11-29 Selecta Biosciences, Inc. Controlled release of immunosuppressants from synthetic nanocarriers
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
KR20140050698A (en) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
CN102336821B (en) * 2011-08-11 2014-10-15 北京永泰免疫应用科技有限公司 New Melan-A epitope peptide and application thereof in preventing and/or treating tumours
JP6081483B2 (en) * 2011-12-12 2017-02-15 セル・メディカ・リミテッド The process of proliferating T cells
WO2013092720A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
RU2485973C1 (en) 2012-02-28 2013-06-27 Общество с ограниченной ответственностью "НТфарма" Recombinant trivalent influenza vaccine
WO2013177440A2 (en) * 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Ordered flagellin array as an immunostimulant
CN104684893B (en) 2012-07-13 2016-10-26 日本波涛生命科学公司 Asymmetric auxiliary group
KR102450907B1 (en) 2012-07-13 2022-10-04 웨이브 라이프 사이언시스 리미티드 Chiral control
RU2677639C2 (en) 2012-07-13 2019-01-18 Шин Ниппон Биомедикал Лэбораториз, Лтд. Chiral nucleic acid adjuvant
CA2936092A1 (en) 2013-01-23 2014-07-31 The Board Of Trustees Of The Leland Stanford Junior University Stabilized hepatitis b core polypeptide
WO2014145205A2 (en) 2013-03-15 2014-09-18 St. Jude Children's Research Hospital Methods and compositions of p27kip1 transcription modulators
MX2015011487A (en) 2013-03-15 2016-02-03 Univ Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom.
BR122020023215B1 (en) 2013-05-03 2022-11-22 Selecta Biosciences, Inc COMPOSITION AND KIT OF TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGEN ANTIGEN
MX2015016691A (en) 2013-06-04 2016-04-04 Selecta Biosciences Inc Repeated administration of non-immunosupressive antigen specific immunotherapeutics.
NZ757210A (en) 2013-09-19 2022-12-23 Zoetis Services Llc Oil-based adjuvants
JP6545177B2 (en) 2013-09-29 2019-07-17 セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド Aryl-substituted aminomethyl spectinomycin analogues as antimicrobial agents
US20170035864A1 (en) * 2013-12-09 2017-02-09 Bullet Biotechnology, Inc. SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF
CN104761644A (en) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 Fusion protein MBP-MART-1 expressed by Escherichia coli, and preparation method and application thereof
JPWO2015108047A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
KR20230152178A (en) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 Chiral design
GB2523187A (en) * 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
EP3160453A1 (en) 2014-06-25 2017-05-03 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
IL292574A (en) 2014-09-07 2022-06-01 Selecta Biosciences Inc Methods and compositions for attenuating anti-viral transfer vector immune responses
JP6715775B2 (en) * 2014-12-25 2020-07-01 国立研究開発法人医薬基盤・健康・栄養研究所 Non-aggregating immunostimulatory oligonucleotide
EP3240801B1 (en) 2014-12-31 2021-01-20 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
CA3010975A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
LT3244920T (en) 2015-01-16 2023-08-25 Zoetis Services Llc Foot-and-mouth disease vaccine
US20180161340A1 (en) 2015-06-18 2018-06-14 St. Jude Children's Research Hospital Methods and compositions for the prevention and treatment of hearing loss
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
WO2017044890A1 (en) * 2015-09-10 2017-03-16 Academia Sinica Bird flu vaccine combination comprising virus-like particles and novel adjuvants
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
US11129882B2 (en) 2015-10-30 2021-09-28 University Of Copenhagen Virus like particle with efficient epitope display
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
US20190046638A1 (en) 2016-04-01 2019-02-14 Checkmate Pharmaceuticals, Inc. Fc RECEPTOR-MEDIATED DRUG DELIVERY
PT3448364T (en) 2016-04-29 2022-05-04 Icahn School Med Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
CA3038089A1 (en) 2016-09-27 2018-04-05 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
JP2020506890A (en) 2017-01-07 2020-03-05 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Patterned administration of immunosuppressants coupled to synthetic nanocarriers
JP2020510687A (en) 2017-03-11 2020-04-09 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Methods and compositions relating to combination treatment with synthetic nanocarriers including anti-inflammatory and immunosuppressive agents
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3694543A1 (en) 2017-10-13 2020-08-19 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
CN112236522A (en) 2018-04-09 2021-01-15 查克美特制药公司 Packaging of oligonucleotides into virus-like particles
CN112771070A (en) 2018-07-16 2021-05-07 西莱克塔生物科技公司 Methods and compositions of OTC constructs and vectors
WO2020018587A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of mma constructs and vectors
CN112639077B (en) * 2018-08-07 2023-06-20 中国科学院生物物理研究所 Method for activating CD4+ T cells
EP3902530A4 (en) * 2018-12-28 2023-01-25 Ramot at Tel-Aviv University Ltd. Polymeric nanovaccines and uses thereof
KR20220008824A (en) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 How to treat anxiety disorders, headache disorders and eating disorders with psilocybin
KR20220004121A (en) 2019-04-28 2022-01-11 셀렉타 바이오사이언시즈, 인크. Methods of treating a subject with pre-existing immunity to a viral transfer vector
BR112021023594A2 (en) 2019-05-28 2022-02-08 Selecta Biosciences Inc Methods and compositions for attenuated antiviral transfer vector immune response
MX2022004825A (en) 2019-10-23 2022-10-10 Regeneron Pharma Synthetic rig-i-like receptor agonists.
DE102020113731B4 (en) * 2020-05-20 2024-02-08 FiberBridge Photonics GmbH Fiberglass and fiberglass product
CA3182002A1 (en) * 2020-06-09 2021-12-16 Charles Richardson Method of making virus-like particle
WO2022098901A1 (en) 2020-11-04 2022-05-12 Selecta Biosciences, Inc. Compositions for reducing immune responses against immunoglobulin proteases
AU2022206197A1 (en) 2021-01-05 2023-07-13 Selecta Biosciences, Inc. Viral vector dosing protocols
JP2024511067A (en) 2021-03-19 2024-03-12 トレインド セラピューティクス ディスカバリー，インコーポレーテッド Compounds and methods of use for modulating trained immunity
JP2024514577A (en) 2021-04-09 2024-04-02 セレクタ バイオサイエンシーズ インコーポレーテッド Synthetic nanocarriers containing immunosuppressants in combination with high affinity IL-2 receptor agonists to enhance immune tolerance
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230140196A1 (en) 2021-10-12 2023-05-04 Selecta Biosciences, Inc. Viral vector dosing protocols
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023183568A1 (en) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
WO2023242155A1 (en) * 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions and methods for the diagnosis of hiv infection
WO2024036324A1 (en) 2022-08-11 2024-02-15 Selecta Biosciences, Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof
WO2024047091A2 (en) 2022-08-30 2024-03-07 Saiba Animal Health Ag Veterinary compositions of modified virus-like particles of cmv and ngf antigens

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3160926D1 (en) 1980-04-15 1983-10-27 Beecham Group Plc Allergens modified with polysarcosines
US5204096A (en) 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
FR2581394B1 (en) 1985-05-02 1988-08-05 Grp Genie Genetique PARTICLES HAVING IMMUNOGENIC PROPERTIES OF THE HBS ANTIGEN AND CARRYING A FOREIGN ANTIGENIC SITE TO THE EPITOPES CARRIED BY THE HBS ANTIGEN, ANIMAL VECTORS AND CELLS FOR THE PRODUCTION OF SUCH PARTICLES AND COMPOSITIONS CONTAINING SUCH PARTICLES FOR THE PRODUCTION
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5143726A (en) 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8903313D0 (en) 1989-02-14 1989-04-05 Wellcome Found Conjugates
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
GB9213601D0 (en) * 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
EP0652890B1 (en) 1992-07-27 1998-01-14 HYBRIDON, Inc. Oligonucleotide alkylphosphonothioates
FR2695563B1 (en) 1992-09-11 1994-12-02 Pasteur Institut Microparticles carrying antigens and their use for the induction of humoral or cellular responses.
GB9227068D0 (en) 1992-12-29 1993-02-24 British Bio Technology Novel proteinaceous particles
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
WO1995029193A2 (en) 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens
PT772619E (en) 1994-07-15 2006-10-31 Univ Iowa Res Found OLIGONUCLEOTIDOS IMUNOMODULADORES
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
EP0879284B1 (en) 1996-01-30 2009-07-29 The Regents of The University of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
GB9702021D0 (en) 1997-01-31 1997-03-19 Imperial College Medicaments
DK1005368T3 (en) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7350798A (en) 1997-04-29 1998-11-24 Universiteit Utrecht Corona virus-like particles as tools for vaccination and therapy
JP2002508748A (en) 1997-05-01 2002-03-19 カイロン コーポレイション Use of virus-like particles as adjuvants
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP4101888B2 (en) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
AU732468B2 (en) 1997-06-23 2001-04-26 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
FR2764826B1 (en) 1997-06-24 1999-09-03 Tempora O METHOD FOR CLEANING POROUS SURFACE, PARTICULARLY STONE, AND SUITABLE COMPOSITION
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
JP4663113B2 (en) 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Use of immunostimulatory oligonucleotides to prevent or reduce antigen-stimulated granulocyte-mediated inflammation
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
US6171591B1 (en) 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
ID26669A (en) 1998-02-12 2001-01-25 Immune Complex Corp INTI HEPATITIS B PROTEINS MODIFIED BY STRATEGY AND ITS DECREASES
ATE356630T1 (en) 1998-04-03 2007-04-15 Univ Iowa Res Found METHOD AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM USING IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINE
US6541438B1 (en) * 1998-05-01 2003-04-01 The Procter & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified cellulase
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
JP2002514397A (en) * 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー Methods for hematopoietic regulation using CpG oligonucleotides
AU761396B2 (en) 1998-06-30 2003-06-05 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
WO2000006588A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
US5962636A (en) 1998-08-12 1999-10-05 Amgen Canada Inc. Peptides capable of modulating inflammatory heart disease
AU777225B2 (en) 1998-09-03 2004-10-07 Coley Pharmaceutical Gmbh G-motif oligonucleotides and uses thereof
JP4486257B2 (en) 1998-10-21 2010-06-23 アメリカ合衆国 Virus-like particles for induction of autoantibodies
US6380364B1 (en) 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
WO2000032227A2 (en) 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
NZ512056A (en) 1998-12-04 2004-01-30 Biogen Inc HBV core antigen particles with multiple immunogenic components attached via peptide ligands
BR9916522A (en) 1998-12-23 2002-12-24 Thompson Boyce Plant Res Vector of expression of plants, cell, plant seed, polynucleotide, immunogenic composition, methods to elicit an immune response in a mammal and to isolate polypeptide, and transgenic plant or plant cell
JP2003523721A (en) 1998-12-31 2003-08-12 カイロン コーポレイション Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof
TR200102493T2 (en) 1999-02-25 2002-02-21 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE.
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
ES2228497T3 (en) 1999-04-19 2005-04-16 Glaxosmithkline Biologicals S.A. ADJUTIVE COMPOSITION INCLUDING SAPONINA AND AN IMMUNO STIMULANT OLIGONUCLEOTIDE.
WO2001016320A1 (en) * 1999-08-30 2001-03-08 Ludwig Institute For Cancer Research Isolated nona and decapeptides which bind to hla molecules, and the use thereof
KR100863630B1 (en) * 1999-09-25 2008-10-15 유니버시티 오브 아이오와 리써치 파운데이션 Immunostimulatory Nucleic Acids
WO2001022990A2 (en) * 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
EP1253942A4 (en) 2000-02-01 2004-06-16 Tanox Inc Cd40-binding apc-activating molecules
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
MXPA02009895A (en) 2000-04-07 2004-09-06 Univ Leeds Innovations Ltd Hepatitis b core antigen fusion proteins.
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
AU6616301A (en) 2000-06-22 2002-01-02 Celltech Pharmaceuticals Ltd Modification of hepatitis b core antigen
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
WO2002053141A2 (en) 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
ES2335979T3 (en) * 2001-09-14 2010-04-07 Cytos Biotechnology Ag IMMUNOSTIMULATOR CPG PACKAGING IN VIRUS SIMILAR PARTICLES: PREPARATION METHOD AND ITS USE.
AU2002347404A1 (en) * 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
EP1432443B1 (en) 2001-10-05 2009-01-21 Cytos Biotechnology AG Angiotensin peptide-carrier conjugates and uses thereof
DK1455593T3 (en) 2001-10-06 2013-08-26 Merial Ltd PROCEDURES AND COMPOSITIONS FOR PROMOTING GROWTH AND INJURY IMMUNITY OF YOUNG ANIMALS
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
EP1513552B1 (en) 2002-06-20 2010-12-01 Cytos Biotechnology AG Packaged virus-like particles in combination with cpg for use as adjuvants with allergens : method of preparation and use
AU2004224762B2 (en) * 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US20060251623A1 (en) * 2003-07-10 2006-11-09 Caytos Biotechnology Ag Packaged virus-like particles
RU2409667C2 (en) * 2004-09-21 2011-01-20 Цитос Биотехнологи Аг Virus-like particles including hybrid protein of ap205 bacteriophage coat protein and antigen polypeptide
EP1973608A1 (en) * 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity

Also Published As

Publication number Publication date
EP1606398A1 (en) 2005-12-21
US20100098722A1 (en) 2010-04-22
AU2004224761A1 (en) 2004-10-07
CN101675993A (en) 2010-03-24
AU2004224762A1 (en) 2004-10-07
MXPA05009289A (en) 2005-10-18
CA2519165A1 (en) 2004-10-07
AU2004223736B2 (en) 2010-05-27
AU2004224762B2 (en) 2009-12-24
CA2517675A1 (en) 2004-10-07
WO2004085635A1 (en) 2004-10-07
BRPI0408623A (en) 2006-03-07
AU2004223736A1 (en) 2004-10-07
ZA200507063B (en) 2007-03-28
ZA200507562B (en) 2006-11-29
JP5022028B2 (en) 2012-09-12
WO2004084939A2 (en) 2004-10-07
CA2517839A1 (en) 2004-10-07
ZA200506541B (en) 2006-12-27
CN1764719A (en) 2006-04-26
EP1605972A2 (en) 2005-12-21
RU2005129727A (en) 2006-03-20
RU2351362C2 (en) 2009-04-10
CN100560719C (en) 2009-11-18
EP1605973B1 (en) 2012-09-26
JP2006523189A (en) 2006-10-12
US7517520B2 (en) 2009-04-14
EP1605973A1 (en) 2005-12-21
KR20050115913A (en) 2005-12-08
WO2004084939A3 (en) 2005-03-31
US20060251677A1 (en) 2006-11-09
NZ542323A (en) 2008-07-31
WO2004084940A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
WO2004084939A8 (en) Hiv-peptide-carrier-conjugates
HK1067058A1 (en) Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
Gomes et al. Harnessing nanoparticles for immunomodulation and vaccines
Lua et al. Bioengineering virus‐like particles as vaccines
Lebel et al. Plant viruses as nanoparticle-based vaccines and adjuvants
De Gregorio et al. Vaccines for the future: learning from human immunology
Butkovich et al. Advancements in protein nanoparticle vaccine platforms to combat infectious disease
ATE494910T1 (en) COMPOSITION COMPRISING PACKAGED VIRUS-LIKE PARTICLES FOR BOOSTING AN IMMUNE RESPONSE
EP1687329B8 (en) Optimized expression of hpv 58 l1 in yeast
WO2002034205A3 (en) Using heat shock proteins to increase immune response
WO2005068639A3 (en) Particle-induced ghrelin immune response
MX2020000221A (en) Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof.
WO2005117983A3 (en) Carrier conjugates of tnf-peptides
WO2008115199A3 (en) Chimeric virus vaccines
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
CA2434000A1 (en) Adjuvant viral particle
WO2009080715A3 (en) Vaccines for malaria
de Vries et al. Phages in vaccine design and immunity; mechanisms and mysteries
Lu et al. Development of foot-and-mouth disease vaccines in recent years
Damodharan et al. A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2
Demotz et al. Native-like, long synthetic peptides as components of sub-unit vaccines: practical and theoretical considerations for their use in humans
UY31574A1 (en) VACCINES AGAINST MALARIA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 41/2004 UNDER (71) THE ADDRESS SHOULD READ "WAGISTRASSE"

WWE Wipo information: entry into national phase

Ref document number: 4109/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2519165

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004224761

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200507562

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 10550580

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2004224761

Country of ref document: AU

Date of ref document: 20040325

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004224761

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004723204

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004723204

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10550580

Country of ref document: US